No connection

Search Results

ACB vs SMTI

ACB
Aurora Cannabis Inc.
BEARISH
Price
$3.43
Market Cap
$194.5M
Sector
Healthcare
AI Confidence
85%
SMTI
Sanara MedTech Inc.
BEARISH
Price
$20.77
Market Cap
$190.4M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ACB
--
SMTI
--
Forward P/E
ACB
-31.18
SMTI
40.73
P/B Ratio
ACB
0.49
SMTI
31.28
P/S Ratio
ACB
0.52
SMTI
1.85
EV/EBITDA
ACB
-6.68
SMTI
18.8

Profitability

Gross Margin
ACB
36.03%
SMTI
92.71%
Operating Margin
ACB
2.32%
SMTI
10.5%
Profit Margin
ACB
-22.51%
SMTI
-36.43%
ROE
ACB
-15.51%
SMTI
-1.75%
ROA
ACB
-4.36%
SMTI
7.1%

Growth

Revenue Growth
ACB
6.8%
SMTI
4.7%
Earnings Growth
ACB
-94.7%
SMTI
--

Financial Health

Debt/Equity
ACB
0.18
SMTI
8.13
Current Ratio
ACB
3.06
SMTI
1.8
Quick Ratio
ACB
1.05
SMTI
1.53

Dividends

Dividend Yield
ACB
--
SMTI
--
Payout Ratio
ACB
0.0%
SMTI
0.0%

AI Verdict

ACB BEARISH

Aurora Cannabis Inc. (ACB) exhibits severe financial distress signals, underscored by a Piotroski F-Score of 1/9—indicating extreme weakness in operational and financial health. The absence of an Altman Z-Score and persistent negative profitability metrics (ROE: -15.51%, ROA: -4.36%) suggest high bankruptcy risk, especially given the company's negative earnings and declining cash flow. Despite a low price-to-book (0.49) and price-to-sales (0.52), the stock trades at a significant discount due to deteriorating fundamentals and a 96.9% 5-year decline. The lack of analyst coverage and neutral insider activity further erode confidence in near-term recovery.

Strengths
Low price-to-book ratio (0.49) suggests potential undervaluation on a balance sheet basis
Strong gross margin (36.03%) indicates efficient production and cost control
High current ratio (3.06) reflects strong short-term liquidity
Risks
Piotroski F-Score of 1/9 indicates severe financial distress and poor operational performance
Negative ROE (-15.51%) and ROA (-4.36%) reflect persistent unprofitability
Earnings growth has collapsed by -94.70% YoY, with a -93.60% Q/Q decline
SMTI BEARISH

SMTI exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 8.13. While the company maintains an impressive gross margin of 92.71%, this is offset by consistent net losses and a track record of massive earnings misses (average surprise of -587.40% over the last 4 quarters). There is a stark disconnect between the 'Strong Buy' analyst consensus and the underlying deterministic health metrics, which suggest high insolvency risk. The stock's long-term price trajectory is sharply negative, despite a recent short-term bounce.

Strengths
Exceptional Gross Margin (92.71%) indicating strong product pricing power
Positive Operating Margin (10.50%) suggesting core business viability
Adequate short-term liquidity with a Current Ratio of 1.80
Risks
Extreme leverage with a Debt/Equity ratio of 8.13
Critical financial health indicated by Piotroski F-Score of 2/9
Chronic inability to meet earnings estimates with severe negative surprises

Compare Another Pair

ACB vs SMTI: Head-to-Head Comparison

This page compares Aurora Cannabis Inc. (ACB) and Sanara MedTech Inc. (SMTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile